With respect to the latest American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) joint guidelines for NSCLC, recommendations of ICI immunotherapy apply to patients who lack driver alterations in EGFR or ALK, as per the condition of histology, PD-L1 status, and/or the presence or absence of contraindications. This evidence concerns the gene ALK and non-small cell lung carcinoma.